Johnson & Johnson Stock: US Bancorp’s Heaviest Healthcare Holding in Q3

Wall St. Watchdog reveals information regarding US Bancorp’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 313 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $1.459 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, US Bancorp reported holding 4,560,669 shares with a market value of $303,375,687. This comprised 1.51% of the total portfolio. On 09/30/2011, US Bancorp reported holding 4,496,594 shares with a market value of $286,388,066. This comprised 1.69% of the total portfolio. The net change in shares for this position over the two quarters is -64,075. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, US Bancorp reported holding 12,541,704 shares with a market value of $258,359,107. This comprised 1.29% of the total portfolio. On 09/30/2011, US Bancorp reported holding 12,360,341 shares with a market value of $218,530,833. This comprised 1.29% of the total portfolio. The net change in shares for this position over the two quarters is -181,363. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, US Bancorp reported holding 3,763,540 shares with a market value of $198,037,471. This comprised 0.99% of the total portfolio. On 09/30/2011, US Bancorp reported holding 3,619,246 shares with a market value of $185,088,238. This comprised 1.09% of the total portfolio. The net change in shares for this position over the two quarters is -144,294. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, US Bancorp reported holding 3,806,120 shares with a market value of $110,225,232. This comprised 0.55% of the total portfolio. On 09/30/2011, US Bancorp reported holding 3,812,459 shares with a market value of $119,634,960. This comprised 0.7% of the total portfolio. The net change in shares for this position over the two quarters is 6,339. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, US Bancorp reported holding 2,348,598 shares with a market value of $82,882,026. This comprised 0.41% of the total portfolio. On 09/30/2011, US Bancorp reported holding 2,369,874 shares with a market value of $77,494,882. This comprised 0.46% of the total portfolio. The net change in shares for this position over the two quarters is 21,276. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, US Bancorp reported holding 2,087,966 shares with a market value of $80,449,327. This comprised 0.4% of the total portfolio. On 09/30/2011, US Bancorp reported holding 1,948,279 shares with a market value of $64,760,797. This comprised 0.38% of the total portfolio. The net change in shares for this position over the two quarters is -139,687. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, US Bancorp reported holding 1,649,341 shares with a market value of $61,899,766. This comprised 0.31% of the total portfolio. On 09/30/2011, US Bancorp reported holding 1,631,629 shares with a market value of $60,321,326. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is -17,712. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, US Bancorp reported holding 717,510 shares with a market value of $41,866,707. This comprised 0.21% of the total portfolio. On 09/30/2011, US Bancorp reported holding 676,462 shares with a market value of $37,178,351. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -41,048. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011, US Bancorp reported holding 400,613 shares with a market value of $33,351,032. This comprised 0.17% of the total portfolio. On 09/30/2011, US Bancorp reported holding 401,202 shares with a market value of $33,051,020. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is 589. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, US Bancorp reported holding 663,110 shares with a market value of $34,203,215. This comprised 0.17% of the total portfolio. On 09/30/2011, US Bancorp reported holding 660,031 shares with a market value of $30,440,629. This comprised 0.18% of the total portfolio. The net change in shares for this position over the two quarters is -3,079. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.

(Note: Data regarding US Bancorp’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>